Apolipoprotein E and Apolipoprotein E Receptors in the Central Nervous System: Relationship with Alzheimer’s Disease

1996 ◽  
pp. 97-102
Author(s):  
B. T. Hyman ◽  
G. W. Rebeck ◽  
R. Christie ◽  
K. Page ◽  
M. Irizarry ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
Apolipoprotein E ◽  
The Central Nervous System

scholarly journals Functions of the Alzheimer’s Disease Protease BACE1 at the Synapse in the Central Nervous System

2016 ◽  
Vol 60 (3) ◽  
pp. 305-315 ◽  
Author(s):  
Kathryn M. Munro ◽  
Amelia Nash ◽  
Martina Pigoni ◽  
Stefan F. Lichtenthaler ◽  
Jenny M. Gunnersen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
The Central Nervous System

Nerve Growth Factor (NGF) in the Central Nervous System: Implications for the Treatment of Alzheimer’s Disease

Brain Repair ◽  
1990 ◽  
pp. 99-112
Author(s):  
Dan Lindholm ◽  
Christine Bandtlow ◽  
Matthias Spranger ◽  
Bastian Hengerer ◽  
Michael Meyer ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Nerve Growth ◽  
The Central Nervous System

scholarly journals CX3CL1/CX3CR1 in Alzheimer’s Disease: A Target for Neuroprotection

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Peiqing Chen ◽  
Wenjuan Zhao ◽  
Yanjie Guo ◽  
Juan Xu ◽  
Ming Yin
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
Early Diagnosis ◽  
Vital Role ◽  
Therapeutic Interventions ◽  
Chemokine Ligand ◽  
The Central Nervous System ◽  
Receptor Cx3cr1

CX3C chemokine ligand 1 (CX3CL1) is an intriguing chemokine belonging to the CX3C family. CX3CL1 is secreted by neurons and plays an important role in modulating glial activation in the central nervous system after binding to its sole receptor CX3CR1 which mainly is expressed on microglia. Emerging data highlights the beneficial potential of CX3CL1-CX3CR1 in the pathogenesis of Alzheimer’s disease (AD), a common progressive neurodegenerative disease, and in the progression of which neuroinflammation plays a vital role. Even so, the importance of CX3CL1/CX3CR1 in AD is still controversial and needs further clarification. In this review, we make an attempt to present a concise map of CX3CL1-CX3CR1 associated with AD to find biomarkers for early diagnosis or therapeutic interventions.

scholarly journals Serum Anticholinergic Activity: A Possible Peripheral Marker of the Anticholinergic Burden in the Central Nervous System in Alzheimer’s Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Koji Hori ◽  
Kimiko Konishi ◽  
Masayuki Tani ◽  
Hiroi Tomioka ◽  
Ryo Akita ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
Cholinergic System ◽  
Lewy Body Dementia ◽  
Compensatory Mechanisms ◽  
Anticholinergic Activity ◽  
The Central Nervous System ◽  
Anticholinergic Burden

We review the utility of serum anticholinergic activity (SAA) as a peripheral marker of anticholinergic activity (AA) in the central nervous system (CAA). We hypothesize that the compensatory mechanisms of the cholinergic system do not contribute to SAA if their system is intact and that if central cholinergic system deteriorates alone in conditions such as Alzheimer’s disease or Lewy body dementia, CAA and SAA are caused by way of hyperactivity of inflammatory system and SAA is a marker of the anticholinergic burden in CNS. Taking into account the diurnal variations in the plasma levels of corticosteroids, which are thought to affect SAA, it should be measured at noon or just afterward.

Sign in / Sign up

Export Citation Format

Share Document